

## Meeting to commence at 9.30 am on Wednesday, 17<sup>th</sup> April 2024 at Cardiff Metropolitan University, Cyncoed Campus, CF23 6XD

## **AGENDA**

		Enclosure
1.	Welcome and introduction	
2.	Apologies	
3.	Declarations of interest	
4.	Minutes of previous meeting	1/AWMSG/0424
5.	Chairman's report (verbal update)	
6.	Feedback on AWTTC Activity:  • AWMSG Medicines Access Review (verbal update)  • NICE terminated appraisals	<b>2</b> /AWMSG/0402
7.	Appraisal – Limited Submission Trifarotene (Aklief®) for cutaneous treatment of Acne Vulgaris of the face and/or the trunk in patients from 12 years of age and older, when many comedones, papules and pustules are present	3/AWMSG/0424 Appendices
8.	National Prescribing Indicators 2023-24. Analysis of prescribing data to September 2023	<b>4</b> /AWMSG/0424
9.	NHS Wales inhaler carbon footprint report – Data to December 2023	<b>5</b> /AWMSG/0424
10.	Update report: National Pharmacogenomics Group	<b>6</b> /AWMSG/0424
11.	Cancer Network – Prevention and Management of Tumour Lysis Syndrome for acknowledgement	<b>7</b> /AWMSG/0424
12.	SBAR: Medicines optimisation resources – process for consideration of resources for review	<b>8</b> /AWMSG/0424
13.	One Wales - Nivolumab monotherapy as a first-line treatment for patients with metastatic deficient mismatch repair (dMMR) / high microsatellite instability (MSI-H) oesophageal and gastric cancer (OW28)	<b>9</b> /AWMSG/0424

- One Wales Dabrafenib and trametinib for the treatment of inoperable BRAF V600E variant anaplastic thyroid cancer (OW27)
- 15. Any other business

Date of next meeting: Tuesday 14th May 2024